Rationale
Since the introduction of zidovudine (AZT) treatment for human immunodeficiency virus type 1 (HIV-1), there has been remarkable progress in the development of therapeutic interventions directed against retrovirus infection. New drugs with a variety of targets have been developed. The targets include viral and host proteins that act on different stages of the HIV-1 life cycle, such as the viral reverse transcriptase, viral integrase, viral protease, envelope and host CCR5 coreceptor. In addition, diverse drug combinations have resulted in many different treatments (FDA, 2013) . This has had a great impact on HIV-1 transmission and disease progression in HIV-1-infected individuals. However, we are currently at a stage when extensive deployment of large-scale antiretroviral drug treatment or prevention is likely (Cohen & Baden, 2012; van der Straten et al., 2012) . Thus, there is potential risk of becoming over-reliant on a limited number of drugs. For example, just one drug, tenofovir, forms a key component of several combination therapies. In this case, resistance could become a significant problem and limit the number of useful treatments, analogous to current trends with antibiotics. It therefore seems timely to consider the search for novel antiretrovirals with targets different from those of the current drugs.
Studies of endogenous retroviruses indicate that retroviruses and their vertebrate hosts have co-existed for tens of millions of years (Stoye, 2012) . During this time, various host factors for resistance to infection have evolved. These are known as restriction factors. Over the last 15 years, several of these factors have been identified and characterized, as well as the counter-strategies that viruses have developed in response to them (Harris et al., 2012; Malim & Bieniasz, 2012; Zheng et al., 2012) . Examples of extensively studied restriction factors include tetherin (prevents virus release), SAMHD1 (reduces intracellular pools of dNTPs, thereby inhibiting reverse transcription) and APOBEC3 (blocks reverse transcription and/or mutates the viral genome) (Fig. 1) . It remains to be determined whether information from these investigations might be useful for the design and development of novel antiretroviral strategies. In this review, we consider this question in the context of a description of the discovery, evolution and properties of one further group of restriction factors, those that inhibit virus replication at early stages of the viral life cycle by interacting with the capsid core of incoming virions. This group includes Fv1, TRIM5a and TRIMCypA (Johnson & Sawyer, 2009) .
is directed to the cell periphery, where it binds to the plasma membrane and coordinates particle assembly; it provides the molecular machinery to ensure the packaging of the viral RNA into the nascent virion, as well as inclusion of the viral enzymes needed for replication such as reverse transcriptase and integrase (reviewed by Balasubramaniam & Freed, 2011) . It recruits the cellular ESCRT (endosomal sorting complex required for transport) machinery needed for membrane pinching off and virus budding. Upon virus release, Gag undergoes viral protease-mediated processing leading to the formation of mature, infectious particles with condensed metastable cores. The shape of these cores differs among retroviral genera; thus, they are conical in lentiviruses like HIV-1 but spherical in gammaretoviruses such as murine leukaemia virus (MLV) and cylindrical in betaretoviruses like Mason-Pfizer monkey virus (Goff, 2001) . Despite their different shapes, the overall architecture of different genera is comparable; they are all composed of hexamers of very similar structure, with the core shape determined by the distribution of 12 pentamers that induce curvature Once the newly formed virus reaches the target cell, the viral envelope protein binds to the cellular receptor leading to membrane fusion and entry of the core into the cell cytoplasm. This is followed by the well-controlled but poorly understood process of core dissolution, known as uncoating, that accompanies reverse transcription and trafficking of viral genetic information to the nucleus (Fassati, 2012) . The relative timing and relationship of these events is still unclear. However, studies investigating the effect on infectivity of HIV-1 core stability reveal that mutations in CA that either overstabilize or destabilize the core result in loss of infectivity and reduced levels of viral DNA synthesis in target cells (Forshey et al., 2002) . Microscopic studies have suggested that CA forms part of the pre-integration complex (PIC) (McDonald et al., 2002) , suggesting a potential role for CA in post reverse transcription stages in the viral life cycle such as nuclear entry and integration. Further evidence of roles for CA in cell trafficking and nuclear import of HIV-1 has also been provided in genetic and biochemical studies (Dismuke & Aiken, 2006 Fig. 1 . Generic retroviral life cycle. Newly synthesized particles undergo a maturation process consisting of proteolytic processing of viral Gag polyprotein, which results in the formation of condensed stable cores. Mature particles enter target cells via membrane fusion, where uncoating, reverse transcription and nuclear transport occur. However, the relative order of these early events is still uncertain. Following nuclear entry of the pre-integration complex (PIC), viral DNA integrates into the host chromosome. Transcription and translation of the provirus lead to synthesis of viral proteins and genomic RNA, which, synchronized by Gag, assemble at the cellular membrane forming new virions. Restriction factors act at different stages of the viral life cycle, for example tetherin inhibits virus release, APOBEC3G blocks reverse transcription and/or mutates the viral genome, and SAMHD1 reduces dNTPs pools affecting reverse transcription. The CA-binding restriction factors Fv1, TRIM5a and TRIMCypA restrict incoming virions at two different steps: before reverse transciption (TRIM5a and TRIMCypA), and after reverse transciption but before integration (TRIM5a and Fv1).
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). In particular, recent evidence strongly suggests that HIV-1 enters the nucleus of non-dividing cells via the interaction of CA with the cytoplasmic nuclear pore complex protein Nup358, potentially influencing the choice of PIC-mediated viral DNA integration site in the host chromosome (Schaller et al., 2011) .
In brief, CA plays many important roles in the viral life cycle. Interestingly, it is CA in this form, assembled in cores, that is thought to represent the target for restriction factors like TRIM5a (Dodding et al., 2005; Forshey et al., 2005) . Unassembled monomeric MLV CA protein expressed in mature form does not interact with Fv1 or TRIM5a.
Discovery and isolation of restriction factors
The initial discovery of CA-binding restriction factors has its origins in pioneering studies in the late 1960s and early 1970s, carried out mostly by Frank Lilly and Wally Rowe to investigate the susceptibility of mice to tumour induction by MLV (Lilly, 1970; Odaka, 1969; Rowe, 1972; Rowe & Hartley, 1972) . Fv1 or Friend virus susceptibility gene 1, was identified and described as a dominant gene that could protect mice from infection with a lethal dose of MLV (Lilly, 1970) . Two major alleles have been described, Fv1 (Pincus et al., 1971 (Pincus et al., , 1975 . Comparison of N-and B-tropic viruses showed that sensitivity to restriction could be mapped to the CA protein (Hopkins et al., 1977; Kozak & Chakraborti, 1996) . It was also shown that Fv1 inhibited virus replication at a stage after reverse transcription but before integration of the viral genome (Jolicoeur & Baltimore, 1976) and that its activity could be saturated, indicating it was present in limited amounts (Duran-Troise et al., 1977) .
The Fv1 gene was cloned in 1996 by a positional cloning approach (Best et al., 1996; Stoye et al., 1995) . It is related to the Gag protein of the MERV-L (murine endogenous retrovirus with a leucine tRNA primer binding site) family of endogenous retroviruses and contains the major homology region sequence, which is highly conserved among retroviral CA proteins (Bénit et al., 1997) .
Fv1 seemed to be present only in mice and to act only on murine viruses. However, the cloning of this gene encouraged the search for similar activities in species other than mouse. An Fv1-like activity was identified in several non-murine mammalian cells that included humans (Towers et al., 2000) . In these cells, replication of N-MLV but not B-MLV was inhibited. The new restriction factor was called restriction factor 1 (Ref1) and, as for Fv1, was dominant and saturable, and sensitivity to restriction could be associated with MLV CA Towers et al., 2000) . Unlike Fv1, Ref1 appeared to act before reverse transcription of the viral genome.
At the same time, restriction of lentiviruses had also been described in primate cell lines (Shibata et al., 1995) . Studies comparing the growth of HIV and simian immunodeficiency virus (SIV) on an extensive panel of cells derived from different primates indicated that, in general, HIV grew better than SIV in cells from New World monkeys, whereas the reverse was true in cells from Old World monkeys (Hofmann et al., 1999) . The new restriction factor was called Lv1. Like Ref1, it was dominant, could be saturated and inhibited virus replication prior to reverse transcription (Besnier et al., 2002; Cowan et al., 2002; Münk et al., 2002) . Once again, the viral determinants of sensitivity to restriction were found to map to the CA protein (Owens et al., 2003) .
In 2004, the Sodroski group isolated a cDNA corresponding to the a isoform of the TRIM5 gene, which possessed the properties expected of the anti-HIV activity described in primate cells (Stremlau et al., 2004) . The gene from rhesus macaques inhibited HIV-1 replication prior to reverse transcription, whereas the human homologue had little or no activity. TRIM5 is a member of a broad family of genes encoding proteins named for the presence of the tripartite motif or RBCC domain comprising RING, B-box and coiled-coil motifs Reymond et al., 2001; Short & Cox, 2006) . TRIM5 contains an additional C-terminal domain linked to the coiled-coil motif called B30.2 or PRYSPRY (Fig. 2) . Further work from different laboratories soon demonstrated that almost all activities previously dubbed Lv1 and Ref1 are mediated by TRIM5a, implying that the same gene is capable of restricting a variety of retroviruses (Hatziioannou et al., 2004b; Keckesova et al., 2004; Perron et al., 2004; Yap et al., 2004) .
Shortly after the discovery of TRIM5a-mediated HIV-1 restriction, the Luban group reported a second anti-HIV-1 activity called TRIMCypA (Sayah et al., 2004) . This was a hybrid factor comprising the RBCC domain of TRIM5a fused to a protein called cyclophilin A (CypA). TRIMCypA is the result of an insertion of a retrotransposed CypA pseudogene into the TRIM5a locus of owl monkeys, a species of New World monkey Sayah et al., 2004) . CypA is a cellular peptidyl propyl isomerase that is important for HIV-1 replication. CypA was identified previously in an early search for Fv1-like factors; it binds HIV-1 CA and can be found in HIV-1 virions (Franke et al., 1994; Luban et al., 1993) . As in the case of TRIM5a, restriction by TRIMCypA occurs before reverse transcription.
Binding and restriction specificity
Fv1 and TRIM5a are very different proteins at the primary sequence level. However, they share several structural features essential for their function as viral restriction factors: they contain an N-terminal dimerization domain connected by a flexible linker (Bishop et al., 2001; Javanbakht et al., 2006a ) to a C-terminal domain responsible for binding their targets (Fig. 2) . A coiled-coil multimerization domain is one characteristic feature of the TRIM motif and is absolutely required for TRIM5a restriction (Langelier et al., 2008; Mische et al., 2005; PerezCaballero et al., 2005) . A coiled coil leading to dimer formation, and required for restriction, is also present in the N-terminal domain of Fv1 (Bishop et al., 2006; Yap et al., 2007) .
Genetic studies have documented the complexity of restriction factor interactions with infecting viruses. TRIM5a from different species shows a remarkable variability in target specificity (summarized in Fig. 3) . Variation in the C-terminal domains of Fv1 (Bishop et al., 2001 ) and TRIM5a appears to underlie this complexity. A given TRIM5a can restrict viruses from different genera of retrovirus, and one particular retrovirus can be restricted by a variety of TRIM5a proteins (Ohkura et al., 2006; Yap et al., 2008) . For example, HIV-1 can be restricted by the orang-utan TRIM5a and by a variety of Old World monkey TRIM5a proteins (pigtailed macaque, sooty mangabey, African green monkey and rhesus macaque), but not by the protein found in humans. In contrast, cotton-top tamarin (New World monkey) TRIM5a can restrict retroviruses across at least three different genera (HIV-1, SIVmac, N-MLV and prototypic foamy virus). With only a limited number of exceptions, each species shows a unique resistance spectrum.
The restriction specificity of TRIM5a is largely, but not exclusively (Li et al., 2007; Newman et al., 2006) , determined by the B30.2 domain in the C terminus of the protein Ohkura et al., 2006; Rahm et (Song et al., 2005b) . Within these regions, there is evidence of positive selection, a high frequency of codon changes resulting in amino acid substitutions compared with synonomous changes in sequence. This is a phenomenon that reflects the evolution of two proteins in conflict with one another, in this case the restriction factor and its viral target (Meyerson & Sawyer, 2011; Sawyer et al., 2005) . In further studies, the variable regions of B30.2 domain were interchanged between TRIM5a from different species, revealing that changes in any of the variable regions could modify the restriction specificity of a given TRIM5a (Ohkura et al., 2006) . Subsequent work has shown that the variable regions form loops on one side of the B30.2 domain (Biris et al., 2012; Yang et al., 2012) , acting independently or in combination to form a binding surface for its viral target.
Residue 110 in MLV CA was initially described to be the primary determinant of sensitivity to restriction in Fv1 and TRIM5a. However, further analyses have documented several other residues of CA as additional determinants of restriction factor sensitivity (Jung & Kozak, 2000; Ohkura & Stoye, 2013; Ohkura et al., 2011; Stevens et al., 2004) . Mapping of all these amino acids on the structure of MLV CA reveals the importance of the exposed surface of CA in the Fv1-CA and TRIM5a-CA interactions, and the significance of charged amino acids for this interaction (Mortuza et al., 2008; Ohkura & Stoye, 2013; Ohkura et al., 2011) .
In the same way as with MLV, lentiviral determinants of sensitivity to TRIM5a restriction map to CA, specifically within surface regions (Hatziioannou et al., 2004a; Kono et al., 2010; Kuroishi et al., 2010; Owens et al., 2004; Song et al., 2007) . Unsurprisingly, SIV determinants for adaptation to growth in rhesus macaques and reduced susceptibility to rhesus macaque TRIM5a restriction are located in the CA protein (Kirmaier et al., 2010; McCarthy et al., 2013) . It is noteworthy that generation of TRIM5a escape mutants is often difficult and associated with fitness costs (Ohkura & Stoye, 2013; Rihn et al., 2013) . Restriction and reduced fitness may both contribute to the effectiveness of TRIM5a in preventing cross-species transmission.
In addition to these and other genetic studies, abrogation experiments in which restriction activity could be saturated with virus-like particles carrying target CA pointed towards a direct interaction of Fv1 and TRIM5a with the retroviral CA (Hatziioannou et al., 2003) . However, demonstrating such a direct interaction proved difficult until it was realized that the probable target for restriction factor was polymerized CA (Dodding et al., 2005; Forshey et al., 2005) with avidity of binding provided by multiple interactions. This enabled the development of a binding assay to assess the interaction between TRIM5a and target . HIV-1 CA was expressed in Escherichia coli, purified and assembled into rods. As TRIM5a is hard to express and purify in bacterial systems (a fact that severely complicated many early studies of TRIM5a function), binding experiments were performed with cell extracts overexpressing transfected TRIM5a. After incubation, tubes were pelleted by ultracentrifugation and any bound proteins analysed by Western blotting. In this way, studies with mutant forms of TRIM5a have assessed the importance of B30.2, the coiled coil and the B-box for efficient binding (Li & Sodroski, 2008; Sastri et al., 2010) . More recently, a similar assay has been developed, allowing the demonstration of a direct interaction between Fv1 and MLV CA assembled on lipid nanotubes (Hilditch et al., 2011) .
From these and related experiments (Bishop et al., 2006; Diaz-Griffero et al., 2009; Goldstone et al., 2013; Li & Sodroski, 2008; Yap & Stoye, 2003) , the following picture of restriction factor binding emerges. TRIM5a binds to the assembled CA of the incoming viral core via its B30.2 domain. The interaction involves most if not all of the surface of both proteins (CA and restriction factor). Individual interactions are of low affinity (Biris et al., 2012), but the multimeric nature of the restriction factor ensures several interactions with assembled CA, resulting in avid binding of incoming virus (Langelier et al., 2008) . Potentially, this strategy allows a single factor to restrict multiple distinct viruses with similar geometries, suggesting that TRIM5a may recognize specific structural patterns ). Fv1 appears to interact with CA in a very similar way. By contrast, TRIMCypA binding is more specific; it interacts with the CypA-binding site, which consists of a loop on the surface of CA (Gamble et al., 1996) . The nature of this interaction can vary from virus to virus and with TRIMCypA from different species (Caines et al., 2012; Goldstone et al., 2010; Ylinen et al., 2010) ; nevertheless, restriction factor multimerization also appears necessary for restriction, probably in order to cross-link CA (Yap et al., 2007) . The degree of multimerization required is likely to depend, at least in part, on the affinity of the interaction of the binding domain and CA (Li et al., 2013b) .
Recently, an electron microscopy study revealed that 2008) and explains the requirements of recognition and self-association for binding and efficient TRIM5a restriction. However, the resolution of the studies performed to date are still of insufficient detail to allow a full molecular understanding of the interaction. It is hoped that future crystallographic studies will provide a more detailed picture of the molecular interactions between TRIM5a and CA.
Mechanisms of restriction
The processes by which CA-binding restriction factors prevent virus replication are still unclear. The Fv1 block was initially delimited to a stage after reverse transcription but before integration. Further studies showed that PICs isolated from restrictive cells retained their ability to integrate viral DNA in vitro (Pryciak & Varmus, 1992) , even though no circular, supercoiled DNA could be detected (Jolicoeur & Rassart, 1980) . As Fv1 is localized exclusively in the cytoplasm (Yap & Stoye, 2003) and DNA circularization is thought to occur only after the PICs enter the nucleus, it seems likely that Fv1 binding results in the inhibition of nuclear entry. However, the precise mechanism of action is still unknown. Thus, Fv1 might act to actively sequester viral nucleic acids en route to the nucleus. Alternatively, it might block the signalling required for nuclear transport.
TRIM5a restriction has been studied more extensively. Nevertheless, the detailed mechanism(s) remains unknown. One of the main effects of TRIM5a binding is the accelerated uncoating of the incoming viral core and inhibition of reverse transcription (Perron et al., 2007; Stremlau et al., 2006) . This finding is supported by in vitro experiments, which show that TRIM5a constructs containing just the B30.2 and the coiled-coil domains induce disruption of CA lattices when bound to them in vitro (Zhao et al., 2011) . Disruption of CA-NC in vitro assemblies can also be achieved via incubation with cell lysates expressing full-length TRIM5a and TRIMCypA (Black & Aiken, 2010) . However, in cells, efficient restriction by TRIM5a requires the B-box domain, which mediates higher-order self-association Li & Sodroski, 2008) .
In addition, the RING domain in TRIM5a shows E3 ubiquitin ligase activity, which, in combination with E2 conjugating enzymes, can ubiquitinate a protein resulting in its degradation within the proteasome. It now appears that TRIM5a self-ubiquitinates and is rapidly degraded by the proteasome Rold & Aiken, 2008) . Several studies link the proteasome to the early effects of TRIM5a on reverse transcription Kutluay et al., 2013; Wu et al., 2006) and a direct association between HIV-1-complexed TRIM5a and proteasomal subunits has been demonstrated (Lukic et al., 2011) . However, this early proteasome-dependent inhibition is not essential for viral restriction, as mutations in the RING domain or drugs that prevent an interaction of TRIM5a with the proteasome relieve the block to reverse transcription, but virus replication is still inhibited at a stage before integration. Lastly, it has been described recently that CA binding by TRIM5a can also act to stimulate the cellular innate immune response by a process involving synthesis of ubiquitin chains by E3 activity of the RING domain. These chains induce activation of the TAK1 kinase complex and NFkB and AP-1 factors, which contribute to the initiation of an antiviral state (Pertel et al., 2011) . It now appears that around half of the known human TRIMs play roles in regulating signalling pathways involved in innate immunity (Versteeg et al., 2013) .
A number of models for the TRIM5a mechanism of action have been described (Fig. 4) . One suggests an accelerated uncoating of incoming viral cores and inhibition of reverse transcription upon TRIM5a binding in a proteasomeindependent manner. Another invokes superlattice formation on viral cores, binding of E2 conjugating enzymes to the RING domain, self-ubiquitination and proteasomal degradation causing premature uncoating of the viral core and failure to reverse transcribe. In this model, TRIM5a would also be able to inhibit virus replication at a later stage, after reverse transcription, by blocking trafficking of the viral core, perhaps in a manner analogous to Fv1. The most recent hypothesis supports activation of innate cellular immune responses upon the formation of a TRIM5a superlattice surrounding the viral core. Further experiments to define how these observations overlap, particularly in infected cells expressing natural levels of TRIM5a, will be crucial to understand the precise mechanism(s) of TRIM5a restriction.
In vivo efficacy of restriction
There is strong evidence that retroviral restriction associated with Fv1, TRIM5a and TRIMCypA in cells has a major impact on the control of retrovirus replication and disease progression in vivo. Fv1 can play a key role in protecting mice against MLV-induced disease by preventing virus replication. A well-studied example is that of AKR mice. These mice carry the Fv1 n allele and normally die from spontaneous leukaemias caused by activation and replication of endogenous N-tropic virus (Nowinski & Hays, 1978; Rowe, 1972; Rowe & Hartley, 1972) . However, the introduction of a single gene, the non-permissive Fv1 b allele, protects mice from virally induced disease (HaranGhera et al., 1993) . However, it seems likely that Fv1 does not act alone; rather, it works by reducing virus replication to an extent that allows the immune system to deal with the threat. This is probably a characteristic of many innate immune systems in that they act in concert with other mechanisms to provide full protection (Zhang et al., 2000) .
As described above, TRIM5a can influence species-specific susceptibility to infection with different retroviruses. Interestingly, rhesus macaques carry at least six different alleles of TRIM5a with different activities against SIV (Newman et al., 2006; Wilson et al., 2008b) . Indeed, virus replication in cell culture and in vivo as well as disease outcome in infected macaques correlate with TRIM5a genotype (Kirmaier et al., 2010; Lim et al., 2010; Reynolds et al., 2011) . Furthermore, TRIM5a drives the same adaptive changes in SIV CA in cell culture and in vivo to allow vigorous growth after infection. These data suggest that host TRIM5a exerts selective pressure on virus during the initial stages of cross-species transmission and confirms the efficacy of its restriction activity in vivo.
Even in the case of human TRIM5a, which presents little activity against HIV-1 in vitro, there are several reports suggesting possible in vivo effects. Among the polymorphisms found in the human gene, the amino acid change H43Y in the RING domain has been associated in at least one study with disease progression in HIV-1-infected individuals (van Manen et al., 2008) . This amino acid change in human TRIM5a also impairs restriction of HIV-1 and N-MLV in cell culture (Javanbakht et al., 2006b; Sawyer et al., 2006) . A different study carried out in South Africa, with a cohort of individuals at high risk of HIV-1 infection, showed that high expression of human TRIM5a was associated with reduced susceptibility to HIV-1 (Sewram et al., 2009) . In addition, it has been suggested that changes of amino acid to proline at positions 119, 159 and 178 of HIV-2 CA are associated with both lower viral loads in infected patients and high viral susceptibility to human TRIM5a restriction in cell culture (Onyango et al., 2010) . However, the precise role for modern-day human TRIM5a, as well as the force(s) driving its evolution (Goldschmidt et al., 2008; Perez-Caballero et al., 2008; Stoye, 2012) , remain a mystery.
TRIMCypA fusion proteins have evolved independently in multiple species of monkeys. Even though the mechanism is comparable, the CypA insertion found in macaques (Brennan et al., 2008; Newman et al., 2008; Virgen et al., 2008; Wilson et al., 2008a) is at a slightly different position downstream of the RBCC-encoding sequences compared with that seen in owl monkeys Sayah et al., 2004) , indicating that they originate from independent retrotranspositions. There is at least one additional insertion in macaques that no longer possesses antiretroviral activity, although phylogenetic reconstructions indicate past activity (Malfavon-Borja et al., 2013 ). An inactive chimaeric gene has also been reported in fish (Boudinot et al., 2011) , although the significance of this observation is still unclear. The widespread distribution and the ability of these chimaeric proteins to restrict a variety of lentiviruses (Goldstone et al., 2010; Ylinen et al., 2010) support the idea that they were selected as a result of their utility in preventing retroviral infections. TRIM5a arranges into superlattices on the CA core, selfubiquitinates and mediates degradation of the TRIM5a-core ensemble by the proteasome. Restriction occurs before reverse transcription. Right: when, however, the proteasome is inhibited, e.g. by the proteasome inhibitor MG132, TRIM5a can also act at a later stage, blocking trafficking of the viral core and nuclear entry.
Utilization
These observations described above indicate that CAbinding restriction factors represent powerful natural retroviral inhibitors that play a role in limiting retrovirus spread. This being the case, can they be used in novel strategies to limit, or prevent, HIV-1 infection? Currently, this seems a long way off, given that the precise mechanism of TRIM5a is still unknown, and the protein is large, difficult to express or purify, and operates intracellularly via multiple weak interactions. Smaller molecules containing just the 'active site' of TRIM5a could be developed, although given the multimeric nature of the restriction factor-CA interaction, it remains an open question as to whether such an approach would be efficacious. Alternatively, it might be possible to retarget human TRIM5a. This would involve the search for compounds that enhance HIV-1 restriction by human TRIM5a. For example, as explained above, human TRIM5a with a single amino acid change, R332P, efficiently restricts HIV-1 . Furthermore, it has been shown that it is R332 that prevents binding rather than P332 that enhances it . Therefore, a molecule that binds to endogenous human TRIM5a neutralizing R332 could potentially increase its affinity for HIV-1. A screen for such compounds could undoubtedly be devised; however, it is not obvious whether a molecule with the desired properties can exist.
The use of gene therapy for HIV-1 treatment is currently being explored. One focus is on methods to deplete the CCR5 co-receptor in haematopoietic stem cells or T-cells with zinc-finger nuclease treatment (Li et al., 2013a) or RNA interference (Boutimah et al., 2013) . Interest in this approach was stimulated by the treatment and apparent cure of a single patient by bone-marrow transplantation using a donor homozygous for the CCR5 co-receptor gene variant D32 (Allers et al., 2011) . Gene therapy might be used to stack genes (Voit et al., 2013) expressing various restriction factors with different targets such as APOBEC3G and TRIMCypA (Chan et al., 2012; Neagu et al., 2009) , thereby reducing the risk of treatment failure due to the appearance of HIV-1 particles using other co-receptors.
Finally, CA-binding restriction factors have evolved independently at least five times in mammals, including Fv1, TRIM5a and three different TRIMCypA genes, indicating that the CA core is a key target for the innate immune response against retroviruses. In addition, other studies, in part stimulated by interest in the mode of action of restriction factors, are increasingly suggesting that the viral core plays multiple roles in the later stages of virus replication to further protect against cellular factors, such as reverse transcription, trafficking and nuclear transport. It is of particular interest that HIV-1 CA mutants with increased or decreased core stability show impaired infectivity and reverse transcription (Forshey et al., 2002) . It would therefore be of significant interest to consider the CA core itself as a drug target (Blair et al., 2010) .
Conclusions
In summary, nature has provided us with several potent viral defence mechanisms. This review has focused mainly on CA-binding restriction factors, but APOBEC, tetherin and SAMHD1 are also of great interest. Substantial efforts have been devoted to unravelling the mechanism and function of such factors. However, it remains a formidable task to utilize the information gathered in these studies for the design of new antiviral strategies, as these factors lack many of the characteristics that can be considered desirable attributes of drug targets. It could be argued that the development of approaches to utilize naturally occurring mechanisms of biological control represents the real challenge for translational research in biomedicine.
